New drug velzatinib versus imatinib for untreated GIST
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial compares a newer cancer drug (velzatinib) with a standard treatment (imatinib) for gastrointestinal stromal tumors (GIST) that cannot be surgically removed or have spread. You would receive one of these two drugs to see which works better and is safer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older
- Confirmed GIST diagnosis that is either metastatic (spread to other parts of body) or cannot be surgically removed
- No prior chemotherapy or targeted therapy for your GIST
- Tumor tissue sample available (archived or fresh biopsy) for testing
- At least one measurable tumor lesion on imaging
- Good overall health and able to follow study procedures and contraception requirements
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called velzatinib for people with advanced gastrointestinal stromal tumor (GIST) that has spread or cannot be removed by surgery. It is for those whose cancer has worsened after trying several standard treatments.
This trial tests a new drug, ziftomenib, combined with imatinib for people with advanced or spreading gastrointestinal stromal tumors (GIST) that have a KIT mutation. It may help if your GIST has gotten worse while on imatinib.
This Phase 2 trial tests whether adding atezolizumab (an immune medicine) to imatinib works better than imatinib by itself in people with advanced gastrointestinal stromal tumors (GIST) that can’t be fully removed and have progressed after standard treatments. It may help by improving how well tumors respond and how long disease stays under control.
This trial tests whether adding a new drug called CGT9486 to sunitinib (a standard cancer drug) works better than sunitinib alone for gastrointestinal stromal tumors (GISTs) that have grown or spread. You may qualify if your GIST stopped responding to or caused problems with imatinib, an earlier treatment.
This trial compares a new oral drug, IDRX-42, with the standard drug sunitinib (Sutent) for people with advanced GIST whose cancer has progressed after imatinib therapy. The goal is to see if IDRX-42 can better control the tumor growth.
This trial studies whether apatinib works better than the usual second-line targeted tablet for advanced gastrointestinal stromal tumor (GIST) after imatinib (or avatinib) no longer works. It may help people whose cancer has grown despite treatment or who couldn’t tolerate it.
Hear when a new Gastrointestinal Stromal Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.